Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The KFF analysis says Medicare spending impacts depend on how Part D plans add coverage for Wegovy, the extent of prior authorization and the number of people who use the drug.
- Simplified Text
-
KFF analysis says Medicare spending depends on Part D plans Wegovy coverage prior authorization drug use
- Confidence Score
- 0.900
- Claim Maker
- KFF
- Context Type
- News Article
- Context Details
-
{ "drug": "Wegovy", "plan": "Part D plans", "factor": "prior authorization", "factor2": "drug use", "organization": "KFF" } - UUID
- 9fdb0126-4d21-42b5-a736-b345849ef47f
- Vector Index
- ✗ No vector
- Created
- September 11, 2025 at 10:27 PM (8 hours ago)
- Last Updated
- September 11, 2025 at 10:27 PM (8 hours ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
51
claims
🔥
8 hours ago
https://www.politico.com/newsletters/politico-pulse/2024/04/24/pharma-lobbying-up-in-2024-00153996
Pharmaceutical industry lobbying spending surged in Q1 2024. Increased spending focuses on PBM reform and other congressional issues. This follows recent government funding bill negotiations.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.